ID

21406

Descripción

Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes; ODM derived from: https://clinicaltrials.gov/show/NCT00454480

Link

https://clinicaltrials.gov/show/NCT00454480

Palabras clave

Versiones (1)
  1. 19/4/17 19/4/17 -
Subido en

19 de abril de 2017

DOI

Para solicitar uno, por favor iniciar sesión.

Licencia

Creative Commons BY 4.0
Comentarios del modelo :

Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.

Volver a los comentarios del modelo
Comentarios de grupo de elementos para :

Comentarios del elemento para :

  • El más nuevo
  • Más antiguo
  • Popular
  • El más nuevo
    • El más nuevo
    • Más antiguo
    • Popular

Sin comentarios

Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.

Eligibility Leukemia NCT00454480

Inglés

Eligibility Leukemia NCT00454480

1 formularios  
  1. StudyEvent: Eligibility
    1. Eligibility Leukemia NCT00454480
Criteria
Descripción

Criteria

diagnosis of 1 of the following:
Descripción

Diagnosis

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0011900
acute myeloid leukemia (aml) meeting the following criteria:
Descripción

Leukemia, Myelocytic, Acute

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0023467
de novo or secondary aml
Descripción

Acute Myelocytic Leukemia de novo | secondary acute myeloid leukemia

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0023467
UMLS CUI [1,2]
C1515568
UMLS CUI [2]
C0280449
no acute promyelocytic leukemia
Descripción

Acute Promyelocytic Leukemia Absent

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0023487
UMLS CUI [1,2]
C0332197
high-risk myelodysplastic syndromes (> 10% marrow blasts; refractory anemia with excess blasts-2)
Descripción

MYELODYSPLASTIC SYNDROME High risk | Bone marrow Blasts Percentage | Refractory anemia with excess blasts II

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C3463824
UMLS CUI [1,2]
C0332167
UMLS CUI [2,1]
C1982687
UMLS CUI [2,2]
C0439165
UMLS CUI [3]
C1318551
no blast transformation of chronic myeloid leukemia
Descripción

Chronic Myeloid Leukemia Blast transformation Absent

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0023473
UMLS CUI [1,2]
C0024262
UMLS CUI [1,3]
C0332197
patients ≤ 60 years of age may be eligible provided they are considered unfit for clinical trial mrc-amli5
Descripción

Age | Unfit Clinical Trial specified

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0001779
UMLS CUI [2,1]
C3841806
UMLS CUI [2,2]
C0008976
UMLS CUI [2,3]
C0205369
patient characteristics:
Descripción

Client Characteristics

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0815172
not pregnant or nursing
Descripción

Pregnancy | Breast Feeding

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0032961
UMLS CUI [2]
C0006147
ast and alt ≤ 2 times upper limit of normal (uln) (for patients receiving gemtuzumab ozogamicin)
Descripción

Aspartate aminotransferase measurement | Alanine aminotransferase measurement | Gemtuzumab ozogamicin

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0201899
UMLS CUI [2]
C0201836
UMLS CUI [3]
C1533699
bilirubin ≤ 2 times uln (for patients receiving gemtuzumab ozogamicin)
Descripción

Serum total bilirubin measurement | Gemtuzumab ozogamicin

Tipo de datos

boolean

Alias
UMLS CUI [1]
C1278039
UMLS CUI [2]
C1533699
creatinine normal (for patients receiving clofarabine)
Descripción

Serum creatinine normal | clofarabine

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0438244
UMLS CUI [2]
C0092777
no other concurrent active malignancy except basal cell carcinoma
Descripción

Malignant Neoplasm | Basal cell carcinoma

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0006826
UMLS CUI [2]
C0007117
prior concurrent therapy:
Descripción

Therapeutic procedure

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0087111
no prior cytotoxic chemotherapy for aml
Descripción

Cytotoxic Chemotherapy Acute Myelocytic Leukemia

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0677881
UMLS CUI [1,2]
C0023467
hydroxyurea or similar low-dose therapy to control wbc count prior to initiation of intensive therapy allowed
Descripción

hydroxyurea | Low-Dose Treatment Similar | White Blood Cell Count | Initiation Therapeutic procedure Intensity

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0020402
UMLS CUI [2,1]
C1708745
UMLS CUI [2,2]
C2348205
UMLS CUI [3]
C0023508
UMLS CUI [4,1]
C1704686
UMLS CUI [4,2]
C0087111
UMLS CUI [4,3]
C0522510
no concurrent enzyme anticonvulsants, including phenytoin, phenobarbital, primidone, carbamazepine, or oxcarbazepine (for patients receiving tipifarnib)
Descripción

Anticonvulsants Enzyme Induction | Phenytoin | Phenobarbital | Primidone | Carbamazepine | oxcarbazepine | tipifarnib

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0003286
UMLS CUI [1,2]
C0014431
UMLS CUI [2]
C0031507
UMLS CUI [3]
C0031412
UMLS CUI [4]
C0033148
UMLS CUI [5]
C0006949
UMLS CUI [6]
C0069751
UMLS CUI [7]
C1176289
Volver a la parte superior de la página

Similar models

Eligibility Leukemia NCT00454480

1 formularios
  1. StudyEvent: Eligibility
    1. Eligibility Leukemia NCT00454480
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de datos
Alias
Item Group
Diagnosis
Item
diagnosis of 1 of the following:
boolean
C0011900 (UMLS CUI [1])
Leukemia, Myelocytic, Acute
Item
acute myeloid leukemia (aml) meeting the following criteria:
boolean
C0023467 (UMLS CUI [1])
Acute Myelocytic Leukemia de novo | secondary acute myeloid leukemia
Item
de novo or secondary aml
boolean
C0023467 (UMLS CUI [1,1])
C1515568 (UMLS CUI [1,2])
C0280449 (UMLS CUI [2])
Acute Promyelocytic Leukemia Absent
Item
no acute promyelocytic leukemia
boolean
C0023487 (UMLS CUI [1,1])
C0332197 (UMLS CUI [1,2])
MYELODYSPLASTIC SYNDROME High risk | Bone marrow Blasts Percentage | Refractory anemia with excess blasts II
Item
high-risk myelodysplastic syndromes (> 10% marrow blasts; refractory anemia with excess blasts-2)
boolean
C3463824 (UMLS CUI [1,1])
C0332167 (UMLS CUI [1,2])
C1982687 (UMLS CUI [2,1])
C0439165 (UMLS CUI [2,2])
C1318551 (UMLS CUI [3])
Chronic Myeloid Leukemia Blast transformation Absent
Item
no blast transformation of chronic myeloid leukemia
boolean
C0023473 (UMLS CUI [1,1])
C0024262 (UMLS CUI [1,2])
C0332197 (UMLS CUI [1,3])
Age | Unfit Clinical Trial specified
Item
patients ≤ 60 years of age may be eligible provided they are considered unfit for clinical trial mrc-amli5
boolean
C0001779 (UMLS CUI [1])
C3841806 (UMLS CUI [2,1])
C0008976 (UMLS CUI [2,2])
C0205369 (UMLS CUI [2,3])
Client Characteristics
Item
patient characteristics:
boolean
C0815172 (UMLS CUI [1])
Pregnancy | Breast Feeding
Item
not pregnant or nursing
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
Aspartate aminotransferase measurement | Alanine aminotransferase measurement | Gemtuzumab ozogamicin
Item
ast and alt ≤ 2 times upper limit of normal (uln) (for patients receiving gemtuzumab ozogamicin)
boolean
C0201899 (UMLS CUI [1])
C0201836 (UMLS CUI [2])
C1533699 (UMLS CUI [3])
Serum total bilirubin measurement | Gemtuzumab ozogamicin
Item
bilirubin ≤ 2 times uln (for patients receiving gemtuzumab ozogamicin)
boolean
C1278039 (UMLS CUI [1])
C1533699 (UMLS CUI [2])
Serum creatinine normal | clofarabine
Item
creatinine normal (for patients receiving clofarabine)
boolean
C0438244 (UMLS CUI [1])
C0092777 (UMLS CUI [2])
Malignant Neoplasm | Basal cell carcinoma
Item
no other concurrent active malignancy except basal cell carcinoma
boolean
C0006826 (UMLS CUI [1])
C0007117 (UMLS CUI [2])
Therapeutic procedure
Item
prior concurrent therapy:
boolean
C0087111 (UMLS CUI [1])
Cytotoxic Chemotherapy Acute Myelocytic Leukemia
Item
no prior cytotoxic chemotherapy for aml
boolean
C0677881 (UMLS CUI [1,1])
C0023467 (UMLS CUI [1,2])
hydroxyurea | Low-Dose Treatment Similar | White Blood Cell Count | Initiation Therapeutic procedure Intensity
Item
hydroxyurea or similar low-dose therapy to control wbc count prior to initiation of intensive therapy allowed
boolean
C0020402 (UMLS CUI [1])
C1708745 (UMLS CUI [2,1])
C2348205 (UMLS CUI [2,2])
C0023508 (UMLS CUI [3])
C1704686 (UMLS CUI [4,1])
C0087111 (UMLS CUI [4,2])
C0522510 (UMLS CUI [4,3])
Anticonvulsants Enzyme Induction | Phenytoin | Phenobarbital | Primidone | Carbamazepine | oxcarbazepine | tipifarnib
Item
no concurrent enzyme anticonvulsants, including phenytoin, phenobarbital, primidone, carbamazepine, or oxcarbazepine (for patients receiving tipifarnib)
boolean
C0003286 (UMLS CUI [1,1])
C0014431 (UMLS CUI [1,2])
C0031507 (UMLS CUI [2])
C0031412 (UMLS CUI [3])
C0033148 (UMLS CUI [4])
C0006949 (UMLS CUI [5])
C0069751 (UMLS CUI [6])
C1176289 (UMLS CUI [7])
Volver a la parte superior de la página 

Contacto

Utilice este formulario para comentarios, preguntas y sugerencias.

Los campos marcados con * son obligatorios.

Ayuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial